A Phase I Trial of iLidcombe: Online Treatment for Young Children Who Stutter

AIM: The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe, a standalone internet version of the Lidcombe Program for young children who stutter. METHOD: We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pretreatment and after 6 months of access. Participants were 20 parents of young children who stuttered. RESULTS: There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favorable, and there was no suggestion of any psychologically adverse impact on children. CONCLUSION: The results of this Phase I trial provide a roadmap for further Phases II-IV clinical trial development.

Authors

Institutions

Publication Details

Journal
American Journal of Speech-Language Pathology
Published
2026-04-27
DOI
https://doi.org/10.1044/2026_ajslp-25-00448
Primary Topic
Stuttering Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Phase I Trial of iLidcombe: Online Treatment for Young Children Who Stutter

Mark Onslow, Ross G. Menzies, Robyn Lowe, Ann Packman et al.
American Journal of Speech-Language Pathology
Stuttering Research and Treatment
article

A Phase I Trial of iLidcombe: Online Treatment for Young Children Who Stutter

Mark Onslow, Ross G. Menzies, Robyn Lowe, Ann Packman, Anna Hearne, Mark Jones, Fiona Ross, Susan O'Brian
article en

Abstract

AIM: The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe, a standalone internet version of the Lidcombe Program for young children who stutter. METHOD: We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pretreatment and after 6 months of access. Participants were 20 parents of young children who stuttered. RESULTS: There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favorable, and there was no suggestion of any psychologically adverse impact on children. CONCLUSION: The results of this Phase I trial provide a roadmap for further Phases II-IV clinical trial development.

American Journal of Speech-Language Pathology
University of Technology Sydney (AU), Bond University (AU)
Openalex Percentile: Top 9%
Stuttering Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.